Pharmaceuticals business segment growth likely to be healthy Recent long term contracts in the radiopharma business as well as Rubyfill traction in the US coupled with Europe launch later this year are expected to strengthen the speciality sub-segment growth, which is likely to grow at 14.7% CAGR in FY20-22E to | 3969 crore on the back of strong growth in the radiopharma business and consolidation of pharmacy business. The CDMO business was impacted in Q4FY20 due to Covid related challenges delaying API dispatches. However, going ahead, we expect this segment to...